Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PARP inhibition in BRCA2-mutated prostate cancer.
Nientiedt C, Tolstov Y, Volckmar AL, Endris V, Bonekamp D, Haberkorn U, Jäger D, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S. Nientiedt C, et al. Among authors: sultmann h. Ann Oncol. 2017 Jan 1;28(1):189-191. doi: 10.1093/annonc/mdw445. Ann Oncol. 2017. PMID: 27687312 Free article. No abstract available.
[Urology in the concept of comprehensive cancer centers].
Hadaschik B, Pahernik S, Grüllich C, Sültmann H, Jäger D, von Kalle C, Duensing S, Hohenfellner M. Hadaschik B, et al. Among authors: sultmann h. Urologe A. 2013 Sep;52(9):1283-9. doi: 10.1007/s00120-013-3313-3. Urologe A. 2013. PMID: 23942742 Review. German.
Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity.
Hoefflin R, Lahrmann B, Warsow G, Hübschmann D, Spath C, Walter B, Chen X, Hofer L, Macher-Goeppinger S, Tolstov Y, Korzeniewski N, Duensing A, Grüllich C, Jäger D, Perner S, Schönberg G, Nyarangi-Dix J, Isaac S, Hatiboglu G, Teber D, Hadaschik B, Pahernik S, Roth W, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Grabe N, Duensing S. Hoefflin R, et al. Among authors: sultmann h. Nat Commun. 2016 Jun 13;7:ncomms11845. doi: 10.1038/ncomms11845. Nat Commun. 2016. PMID: 27291893 Free PMC article.
Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression.
Pickl JM, Tichy D, Kuryshev VY, Tolstov Y, Falkenstein M, Schüler J, Reidenbach D, Hotz-Wagenblatt A, Kristiansen G, Roth W, Hadaschik B, Hohenfellner M, Duensing S, Heckmann D, Sültmann H. Pickl JM, et al. Among authors: sultmann h. Oncotarget. 2016 Sep 13;7(37):59589-59603. doi: 10.18632/oncotarget.10729. Oncotarget. 2016. PMID: 27449098 Free PMC article.
Mutations in BRCA2 and taxane resistance in prostate cancer.
Nientiedt C, Heller M, Endris V, Volckmar AL, Zschäbitz S, Tapia-Laliena MA, Duensing A, Jäger D, Schirmacher P, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S. Nientiedt C, et al. Among authors: sultmann h. Sci Rep. 2017 Jul 4;7(1):4574. doi: 10.1038/s41598-017-04897-x. Sci Rep. 2017. PMID: 28676659 Free PMC article.
Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy.
Dietz S, Sültmann H, Du Y, Reisinger E, Riediger AL, Volckmar AL, Stenzinger A, Schlesner M, Jäger D, Hohenfellner M, Duensing S, Grüllich C, Pahernik S. Dietz S, et al. Among authors: sultmann h. Oncotarget. 2017 May 23;8(43):74049-74057. doi: 10.18632/oncotarget.18200. eCollection 2017 Sep 26. Oncotarget. 2017. PMID: 29088767 Free PMC article.
220 results